Other grades of this product :
| 3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole Basic information |
| Product Name: | 3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole | | Synonyms: | 3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole;Anle138b;3-(benzo[d][1,3]dioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole;5-(3-bromophenyl)-3-(3,4-methylenedioxyphenyl)-1H-pyrazole;ANLE-138B; ANLE 138B;1H-Pyrazole, 3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-;Anle138b >=98% (HPLC);Emrusolmin | | CAS: | 882697-00-9 | | MF: | C16H11BrN2O2 | | MW: | 343.17 | | EINECS: | | Product Categories: | APIS | | Mol File: | 882697-00-9.mol |
| 3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole Chemical Properties |
| Boiling point | 527.3±50.0 °C(Predicted) | | density | 1.567±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | Soluble in DMSO (up to 15 mg/ml with warming). | | form | powder | | pka | 12.57±0.10(Predicted) | | color | white to beige | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months. |
| 3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole Usage And Synthesis |
| Description | Anle138b (882697-00-9) is an aggregation inhibitor that modulates the formation of pathological oligomers of both prion and α-synuclein.1?In mouse models of prion diseases and Parkinson’s disease, Anle138b strongly inhibited oligomer formation, neuronal degeneration, and disease progression even after disease onset.1,2?Anle138b has delayed disease progression and prevented motor decline in multiple neurodegenerative models.3-6?Treatment of melanoma cells with anle138b caused massive cell death via major dysregulation of autophagy revealing a protective effect of α-synuclein on autophagy in these cells.7?Orally bioavailable and able to cross the blood-brain barrier. | | Uses | Anle 138b is an anti-aggregating compound previously shown to delay the onset of scrapie, a transmissible prion disease. A protein aggregation inhibitor. | | Biochem/physiol Actions | Anle138b, an oligomer modulator, inhibits neuronal degeneration. It rescues neurons from the aggregation?effects of α-synuclein. | | References | 1) Wagner?et al.?(2013),?Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease;?Acta Neuropathol.,?125?795
2) Levin?et al.?(2014),?The oligomer modulator anle138b inhibits disease progression in a Parkinson’s mouse model even with treatment started after disease onset; Acta Neuropathol.,?127?779
3) Wagner?et al.?(2015),?Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies; Acta Neuropathol.,?130?619
4) Martinez Hernandez?et al.?(2018),?The diphenylpyrazole compound anle138b blocks Aβ channels and rescues disease phenotypes in a mouse model for amyloid pathology; EMBO Mol. Med.,?10?32
5) Heras-Garvin?et al.?(2019),?Anle138b modulates α-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy; Mov. Disord.,?34?255
6) Brendel?et al.?(2019),?Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer’s disease tau; Alzheimer’s Res. Ther.,?11?67
7) Turriani?et al.?(2017),?Treatment with diphenyl-pyrazole compound anle138b reveals that α-synuclein protects melanoma cells from autophagic cell death; Proc. Natl. Acad. Sci. USA,?114?E4971 |
| 3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole Preparation Products And Raw materials |
|
日本语
한국어
Français
Deutsch
España
Türkiye